AmeriHealth Caritas Urges Americans to Reduce Coronavirus Risk by Quitting Smoking and Vaping
Behaviors compromise lung health, can increase vulnerability to COVID-19 infection
Philadelphia, Pa. —AmeriHealth Caritas, a national leader in Medicaid managed care and other health care solutions for those most in need, cautions that electronic cigarette (e-cigarette) use can lead to poorer health outcomes for people living below the federal poverty level, who are disproportionately affected by smoking-related health issues.
Some health officials are becoming increasingly alarmed by the possibility that vaping could make COVID-19 worse. Vaping, the use of e-cigarettes, can cause dangerous lung and respiratory problems, which could aggravate the symptoms of COVID-19.
At a recent press briefing on COVID-19, Dr. Sharon Watkins of the Pennsylvania Department of Health cautioned, “We do know that vaping is related to lung injury and lung injury is one of the risk factors for more severe presentation in COVID-19.” Watkins, the PA State Epidemiologist, said smokers should reduce or stop vaping to avoid COVID-19 complications.
Smoking has been designated as an underlying medical condition by the Centers of Disease Control and Prevention (CDC) because it weakens the immune system, which increases the risk for severe illness from COVID-19.[i] The American Lung Association also believes smokers are a high-risk group.
“COVID-19 is a respiratory disease, it attacks the lungs. That means people who smoke regular cigarettes, marijuana or vape should take extra precautions and consider themselves at higher risk for complications from COVID-19,” said Deborah Brown, chief mission officer of the American Lung Association. “And that means that there has never been a better time to quit smoking — use this current disruption of your regular schedule to create a new tobacco and smoke-free plan.”
Even prior to the COVID-19 pandemic, vaping was deemed a growing public health issue, said Dr. Andrea Gelzer, senior vice president of medical affairs at AmeriHealth Caritas. The Food and Drug Administration (FDA) banned the sale of fruit, dessert and mint-flavored e-cigarette pods which are popular with teenagers, but exempted menthol-flavored pods containing nicotine for adult users who may be trying to make a switch from traditional cigarettes.[ii]
“We are at risk of having a generation with significant respiratory problems caused by vaping,” Dr. Gelzer said. “People are becoming addicted to nicotine through vaping, which is not a safe or viable smoking cessation strategy.”
Through the first two months of the year there already were more than 2,800 lung injury cases and about 70 deaths in the United States and the District of Columbia associated with the use of e-cigarettes, according to the Centers of Disease Control and Prevention (CDC). The aerosol created by e-cigarettes can contain harmful substances, including nicotine, heavy metals like lead, volatile organic compounds and cancer-causing agents.
Like traditional combustible cigarettes, e-cigarettes are being marketed and sold in retail locations concentrated in communities “at higher risk for adverse health outcomes, including communities whose residents have lower incomes, greater racial diversity, and lower educational attainment,” according to a recent report by the Public Health Law Center, a St. Paul, Minn.-based organization that provides legal and policy analysis to support efforts to reduce and eliminate commercial tobacco products.
Dr. Gelzer said e-cigarette use may worsen existing health disparities in vulnerable communities, especially those that have been disproportionately affected by smoking-related diseases and who have been historically targeted by tobacco marketers.
“We encourage and provide assistance to our members to quit smoking – including free cessation counseling and nicotine replacement products – because it is important to protect one’s health,” she said. “Nicotine is highly addictive and it can be very difficult to quit. There are safer and more effective methods for quitting smoking than e-cigarettes.”
About AmeriHealth Caritas AmeriHealth Caritas is one of the nation’s leaders in health care solutions for those most in need. Operating in 13 states and the District of Columbia, AmeriHealth Caritas serves approximately 4 million Medicaid, Medicare and Children’s Health Insurance Program (CHIP) members through its integrated managed care products, pharmaceutical benefit management and specialty pharmacy services, and behavioral health services. Headquartered in Philadelphia, AmeriHealth Caritas is a mission-driven organization with more than 35 years of experience serving low-income and chronically ill populations. For more information, visit www.amerihealthcaritas.com.
GOING TO A MED SPA OR A DOCTOR’S OFFICE FOR A PEEL IS SO PASSE
WHY NOT HAVE ONE CUSTOMIZED AND DELIVERED TO YOUR DOOR ?
Peels are one of the most effective and least invasive paths to better skin. Specially formulated with gentle acids and other pure ingredients, they clarify and beautify by removing dead surface layers, enabling skin to heal and renew itself from within. In order to receive peels that are truly effective, skin care devotees must go to a physician’s office or med-spa to receive a peel with sufficient strength to deliver maximum results. With approximately $36.5 million Americans unemployed paying $125.00 or more a month for an in-office peel is a luxury most cannot afford. In addition, due to COVID there are many who do not feel comfortable having a procedure performed that entails being inside with no mask on with an aesthetician inches away from their face.
Although a plethora of skincare companies offer versions of peels in a pad form, most offer low concentrations of the active formulas and high PH’s that render the formulas less effective. What’s more, the method of applying these “peels” is not the same as what is done in a doctor’s office or med spa. Perfect Image is one of the first beauty companies, whose products were formulated by a chemist, to deliver custom peels to your doorstep that provide the same efficacy as in-office peels at a mere fraction of the price.
Cost: $29.95 for 30 ML or approximately 15-30 peel applications. Average use is 1-2 ML per treatment.
How does the process work? If customers have had professional peels performed and they are familiar with the strength used on their skin they can choose from 10%, 30% or 50% glycolic peels. If the process is new to them, or they have questions, they can chat online with a licensed aesthetician who they can send pictures to so that the aesthetician can recommend the strength best suited to their skin, as well as suggest pre-peel and post-peel products.
The product application- 99% of the peels that are available on the market come in a pad form and are meant to be swiped across the face.
Perfect Images does offer peels in a pad form as well, which are just as effective as their bottled formula. They are pads that are pre-soaked with the liquid gel peel. Just because they are in pad form, does not mean it lessens the effectiveness. The biggest difference from Perfect Image’s version compared to those on the market is the concentration of acid (most are 10% or lower concentration), and a higher pH typically 3.5 and higher which dilutes the formula. Perfect Image has a lower PH range from 2-2.5pH. to keep the integrity of the active ingredients.
Perfect Image products come in a liquid gel form in a “tincture” bottle and are left on the face for a maximum of 1 minute if it’s your first treatment. Then, users typically slowly increase the contact time on the skin and or number of layers on subsequent treatments. When layering the peel, it can be as effective or comparable to a peel in a spa or treatment center. Layers refer to how many times you wipe the peel over the same area in a single treatment. With each wipe, the peel intensifies and penetrates the skin a little deeper until neutralized or reaches a certain depth based on pH and skin type. Layering is only recommended for those who are comfortable with peels or have more experience, and have used the peel several times without complications. You can continue layering up to 2-5 layers depending on peel and skin tolerance. Perfect Image always recommends that its customers build up a tolerance before layering.
This is how peels are applied professionally. The products come with clear instructions to spot test on a small patch of skin such as under the chin or an area close to the treatment area, before applying to the face. Once it is determined that the skin reacts well to the product, it can be used on the face, shoulders, decollete, and tops of the hands.
Benefits:
Reduces the appearance of wrinkles and fine lines
Improves skin hydration
Improves Scars
Reduces Pore Size
Helps to Reduce Acne
Reduces Hyperpigmentation
Stimulates collagen development for plumper, firmer skin
Increases cellular turnover for smoother skin
Each product is packed with natural plant/ botanical extracts.
The “beauty” of Perfect Image Products is how they are made
Paraben Free
Gluten Free
Phalate Free
Cruelty Free
Made in The USA
*** 70% peel is available for professional purchase only
Cornucopia Campaign Elevates the Country's Top-Rated Dairy Producers Empowering a consumer response to the “factory-farm takeover” of organic agriculture
Earl Ransom (above) and Amy Huyffer of Strafford Organic Creamery, one of Cornucopia’s top-rated dairies, are committed to the guiding principles of organic agriculture. They pay close attention to building soil fertility, protecting their watershed, and managing their beloved herd of Guernsey cows with animal welfare as a top priority. (Photo by Rachel Zegerius during a recent visit to top-rated dairies in Vermont)
The Cornucopia Institute is launching a new campaign to showcase dairy producers who use the most ethical, authentic organic farming practices.
The Organic Innovators: Top-Rated Farmers You Can Trust” Dairy Campaign will empower consumers and wholesale buyers to support hard-working farmers who are in danger of being washed off the land by a tidal wave of surplus organic milk, stemming from the rise of factory farms certified under the USDA organic label.
The campaign builds on Cornucopia’s Organic Dairy Scorecard, used by thousands of consumers monthly to make food shopping decisions that invest in responsible stewardship of environmental and human health. This consumer tool is based on up-to-date research of the organic dairy industry and rates over 160 organic dairy brands and private-label products.
“Authentic organic dairies lack the multimillion-dollar marketing budgets of their industrial competitors,” says Marie Burcham, Cornucopia’s director of domestic policy. “Cornucopia aims to elevate the critical role these dairies play in the marketplace and in our communities.”
The campaign will prioritize exemplary management practices that set top-rated farms apart from other organic dairy farms and provide a more nutritious, value-added product to consumers.
“Your food choices matter,” Burcham says. “If you have the access, buying from our top-rated brands serves as an investment in our collective health, decentralized food production, and the future of the planet while safeguarding the livelihoods of ethical, organic dairies.”
As the specter of food shortages hovers, local farms have been busier than ever and are not hobbled by the complicated supply chains of industrialized food production.
Cornucopia is committed to the preservation and protection of public health; access to clean, nutrient-dense food; and the livelihoods of authentic organic farmers who contribute to the health of their communities, animals, plants, and soil.
Read our profiles on Seven Stars Farm (Phoenixville, Pennsylvania), Thistle Hill (North Pomfret, Vermont), and Strafford Organic Creamery (Strafford, Vermont) on Cornucopia’s Farmer Spotlight page. Stay tuned to follow our ongoing “Organic Innovators” Dairy Campaign, which will include additional profiles and issue-specific research.
See how your favorite dairy brand rates on our mobile-friendly scorecard. If your favorite organic brand isn’t on this list, please let us know at cultivate@cornucopia.org.
COVID-19: An additional contribution to the testing landscape in Canada
Roche's Elecsys® Anti-SARS-CoV-2 serology test authorized under Health Canada's Interim Order making it available to Canadian laboratories, healthcare professionals and patients.
LAVAL, QC, June 9, 2020 /CNW Telbec/ - The new Elecsys® Anti-SARS-CoV-2 antibody test now available in Canada is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2.
The high specificity of this test is crucial to determine reliably if a patient has developed antibodies related to an infection with the SARS-CoV-2 virus.
This serology test has a specificity greater than 99.8% and sensitivity of 99.5% (14 days post-PCR confirmation).
The Elecsys® Anti-SARS-CoV-2 serology test has the largest clinical studies program with 10,453 samples tested.
The fully automated test offers a quick turnaround time and is available on all Roche's high throughput cobas e analyzers which are widely available across Canada.
Roche's extensive global manufacturing capabilities provide tests in the high double-digit millions since last May.
The tests which are manufactured in Germany and shipped directly to Canada will make a significant contribution in the country.
''We have worked closely with the regulatory authorities to accelerate access to the SARS-CoV-2 serology test in Canada. Laboratory tests are critical to support the Canadian healthcare system in the fight against COVID-19.'' said Andrew Plank, President and General Manager, Roche Diagnostics, division of Hoffmann-La Roche Limited. '' I am proud of the high specificity and sensitivity of the new Elecsys® Anti-SARS-CoV-2 antibody test, which is critically important and brings a reliable tool to better manage the COVID-19 health crisis.''
Mr. Plank added that with this announcement, Roche invites interested parties to participate in its Seroprevalence Study Program where several opportunities can be offered to those who qualify for the program.
Public Health, hospital and private laboratories will be able to run the Elecsys® Anti-SARS-CoV-2 serology test on Roche's cobas e analyzers, which are already widely available across Canada, and in each province. These fully automated systems can provide Anti-SARS-CoV-2 test results in approximately 18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyzer.
The Roche's Anti-SARS-CoV-2 test covers a wider span of the immune response against this virus from early on with IgM production to later with IgG with a detection design optimized to bind high affinity antibodies. It has a specificity greater than 99.8% and 99.5% sensitivity1 (14 Days post-PCR confirmation), which can help assess patients' immune response to the virus. Also, the Elecsys® Anti-SARS-CoV-2 serology test has the largest clinical studies program with 10,453 samples tested2. As more is understood about immunity to SARS-CoV-2, this test may help to assess who has potentially developed immunity to the virus.
About Roche's contribution to the fight against COVID-19 in Canada We are fully committed to further support Canada's fight against COVID-19 with the launch of this new serology test. This test is a complement to our existing molecular cobas® SARS-CoV-2 test, authorized under Health Canada's Interim Order, which detects the novel coronavirus SARS-CoV-2 with our automated, high-throughput cobas 6800/8800 platforms. We also supply other SARS-CoV-2 test solutions that are made available for lower volume testing on the MagNA Pure and LightCycler systems (Research Use Only) and we continue to work on expanding our portfolio of COVID-19 test solutions.
Patterns of typical abnormalities in routine laboratory testing have been identified in case series of hospitalized COVID-19 patients, which have been associated with poor clinical outcomes. Through our broad clinical biochemistry menu, we provide biomarkers such as D-Dimer, glucose, Interleukin-6 (IL-6), procalcitonin (PCT), lactate dehydrogenase (LDH) and C-reactive protein (CRP). These biomarkers can help clinicians decide when more aggressive critical care support must be considered or on the contrary when stepping down of treatment may be an appropriate course of action.
In addition to testing, creative ideas have emerged with the collaboration of the community and industry partners. With the COVID-19 Open Innovation Challenge, we called the innovative minds in Canada to bring forward solutions to address the crisis, and with the support of the SCALE AI Supercluster, we are working with IVADO Labs on optimizing the distribution of diagnostic tests for COVID-19 with an AI-powered allocation optimization tool. We also believe that an important way in which we can win this fight is through the sharing of knowledge and healthcare data to better inform patient care and health system decision making. With the Roche Data Science Coalition, we aim to bring actionable COVID-19 intelligence to patients, frontline healthcare providers, institutions, supply chains, and governments.
With a majority of medical decisions being based on lab results, the importance of diagnostics testing within the healthcare system that exists under normal circumstances has been further reinforced during the pandemic.
It has also generated better collaboration between the private and public healthcare stakeholders and a faster adoption of new technologies for the benefit of the patient.
About antibody testing An antibody test, also called a serology test, is used to determine whether a person might have gained immunity against a pathogen or not. The human body makes antibodies in response to many illnesses. In the current situation of the COVID-19 pandemic, antibody tests need to be able to specifically detect antibodies against SARS-CoV-2 with no cross-reactivity to other similar coronaviruses, which could generate a false positive result and thus wrongly indicate potential immunity. A false positive result happens when a person receives a positive test result, when they should have received a negative result. False positives are particularly critical when we do not know how many people in a given population have been exposed to the virus. As of 24 April 2020, no study has evaluated whether the presence of antibodies to SARS-CoV-2 confers immunity to subsequent infection by this virus in humans3.
About Elecsys® Anti-SARS-CoV-2 serology test4 Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in-vitro qualitative detection of antibodies (including IgG) to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human serum and plasma. Through a blood sample, the test, which is based on an in-solution double-antigen sandwich format, can detect antibodies to the new coronavirus causing COVID-19, which could signal whether a person has already been infected and potentially developed immunity to the virus. Based on the measurement of a total of 10,453 samples, the Elecsys® Anti-SARS-CoV-2 assay has 99.80% specificity and shows no cross-reactivity to the four human coronaviruses causing common cold. This means it can lower the chance of false positives due to the detection of similar antibodies that may be present in an individual, but are specific for coronaviruses other than SARS-CoV-2. Elecsys® Anti-SARS-CoV-2 detected antibodies with 99.5% sensitivity in samples taken 14 days after a PCR-confirmed infection. The importance of specificity and sensitivity of a particular test will be dependent on its purpose and disease prevalence within a given population.
About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognized as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1]
Full specifications of Roche's Elecsys® Anti-SARS-CoV-2 antibody test and immunoassay systems, including throughput, can be found on our diagnostics.roche website
[2]
For more information, please refer to Package insert of Elecsys Anti-SARS-CoV-2
For more information, please refer to Package insert of Elecsys Anti-SARS-CoV-2
SOURCE Roche Diagnostics
Smart.Vet joins forces with Merck Animal Health and Royal Canin to bring virtual care to Canadian veterinary hospitals
Thanks to a combined partnership between all three companies, a 50% discount off the base subscription price will be offered to all Canadian veterinary hospitals for a period of 60 days.
BURLINGTON, ON, June 9, 2020 /CNW/ - Smart.Vet announced today that they are partnering with Merck Animal Health and ROYAL CANIN®. This relationship will allow Smart.Vet to offer their virtual care platform to veterinary clinics at 50% of the regular cost for 2 months. Both Merck Animal Health and Royal Canin are dedicated to assisting veterinarians during the COVID-19 pandemic.
"During the pandemic, companies from the veterinary industry need to combine their efforts in order to better assist veterinarians, said Marylin Merit, Associate Marketing Director at Merck Animal Health Canada. That's why we have decided to work together with Royal Canin towards a common goal: facilitate clinic and pet owner access to a virtual care platform, thereby maintaining the level of care that pets deserve."
"What's particularly exciting," said David Brooks, Veterinary Marketing Director at Royal Canin Canada, "is that this technology makes it very simple for veterinary team members to stay connected with their patients. And it opens up all kinds of new opportunities such as feline medicine, nutrition or weight-loss consultations and follow-ups."
Together, Merck Animal Health, Royal Canin, and Smart.Vet Offer:
A world-class virtual care solution that allows veterinary clinics to schedule, perform, and accept payment for telehealth consultations.The Smart.Vet platform equips clinics with a fully clinic branded web application that includes online scheduling (directed by clinics and clients), communication (video, phone, and message) between veterinary staff and pet owners, and built-in eCommerce.
50% off Platform Base Subscription Price allows a clinic to join for only $49/month for the first 2 months. There are no implementation or consultation fees. This applies to all existing and new clinics paying the standard rate.
3 Virtual Care Webinars with industry professionals discussing the future of telehealth, it's implications for the industry and the benefits of a formal platform. Each session will conclude with a Q & A with our panelists. To register for a webinar, please see below.
"Our relationships with Merck Animal Health and Royal Canin constitute a major milestone in Smart.Vet's evolution as a worldwide virtual care provider for veterinary clinics", said Dr. Sharon Quinn, co-founder of Smart.Vet. "Partnering with Royal Canin and Merck Animal Health brings technology, pharmaceuticals, and pet nutrition into a single collaborative unit. Part of our mission moving forward is to work together on developing new innovative methods of delivering virtual care for pets that include nutrition and pharmaceuticals."
The collaboration between Smart.Vet, Merck AH, and Royal Canin will enable hundreds of clinics to provide virtual care to their clients at a reduced cost. This will allow most clinics to begin to achieve ROI using their Smart.Vet Online Health Centres after performing just one consultation.
The Smart.Vet platform has enabled clinics to perform over 10,000 telehealth consultations since April 1st and has client clinics in Canada, the United States, Europe, Singapore, and Australia.
Smart.Vet joins forces with Merck Animal Health and Royal Canin to bring virtual care to Canadian veterinary hospitals
Thanks to a combined partnership between all three companies, a 50% discount off the base subscription price will be offered to all Canadian veterinary hospitals for a period of 60 days.
BURLINGTON, ON, June 9, 2020 /CNW/ - Smart.Vet announced today that they are partnering with Merck Animal Health and ROYAL CANIN®. This relationship will allow Smart.Vet to offer their virtual care platform to veterinary clinics at 50% of the regular cost for 2 months. Both Merck Animal Health and Royal Canin are dedicated to assisting veterinarians during the COVID-19 pandemic.
"During the pandemic, companies from the veterinary industry need to combine their efforts in order to better assist veterinarians, said Marylin Merit, Associate Marketing Director at Merck Animal Health Canada. That's why we have decided to work together with Royal Canin towards a common goal: facilitate clinic and pet owner access to a virtual care platform, thereby maintaining the level of care that pets deserve."
"What's particularly exciting," said David Brooks, Veterinary Marketing Director at Royal Canin Canada, "is that this technology makes it very simple for veterinary team members to stay connected with their patients. And it opens up all kinds of new opportunities such as feline medicine, nutrition or weight-loss consultations and follow-ups."
Together, Merck Animal Health, Royal Canin, and Smart.Vet Offer:
A world-class virtual care solution that allows veterinary clinics to schedule, perform, and accept payment for telehealth consultations.The Smart.Vet platform equips clinics with a fully clinic branded web application that includes online scheduling (directed by clinics and clients), communication (video, phone, and message) between veterinary staff and pet owners, and built-in eCommerce.
50% off Platform Base Subscription Price allows a clinic to join for only $49/month for the first 2 months. There are no implementation or consultation fees. This applies to all existing and new clinics paying the standard rate.
3 Virtual Care Webinars with industry professionals discussing the future of telehealth, it's implications for the industry and the benefits of a formal platform. Each session will conclude with a Q & A with our panelists. To register for a webinar, please see below.
"Our relationships with Merck Animal Health and Royal Canin constitute a major milestone in Smart.Vet's evolution as a worldwide virtual care provider for veterinary clinics", said Dr. Sharon Quinn, co-founder of Smart.Vet. "Partnering with Royal Canin and Merck Animal Health brings technology, pharmaceuticals, and pet nutrition into a single collaborative unit. Part of our mission moving forward is to work together on developing new innovative methods of delivering virtual care for pets that include nutrition and pharmaceuticals."
The collaboration between Smart.Vet, Merck AH, and Royal Canin will enable hundreds of clinics to provide virtual care to their clients at a reduced cost. This will allow most clinics to begin to achieve ROI using their Smart.Vet Online Health Centres after performing just one consultation.
The Smart.Vet platform has enabled clinics to perform over 10,000 telehealth consultations since April 1st and has client clinics in Canada, the United States, Europe, Singapore, and Australia.
FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)
Award acknowledges FACIT's commercialization impact in growing Ontario's life sciences industry
TORONTO, June 9, 2020 /CNW/ - FACIT, a commercialization venture firm, has been nationally recognized with CVCA's 2020 Venture Capital Regional Impact Award for Ontario. The CVCA helps to set the foundation for greater collaboration, innovation, growth and market intelligence for Canadian private capital professionals. The Venture Capital Regional Impact Award celebrates firms whose investments have positioned portfolio companies to make a meaningful mark within both their community as well as the broader niche sector. The award competition considers the most impactful private equity organizations across all sectors including IT, AgTech, Healthcare, and CleanTech.
FACIT's award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics ("Propellon") and Triphase Accelerator ("Triphase"), and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company). The partnership represents one of the largest oncology licensing transactions for a preclinical asset in Canadian history, and the largest biotech asset transaction worldwide for academia. Moreover, this deal helped to solidify a "made in Ontario" development pathway for commercialization of oncology innovations, as the asset at the heart of the transaction originated from FACIT's strategic partner, the Ontario Institute for Cancer Research (OICR). FACIT's strategic seed investment of $3M was critical in putting Ontario intellectual property (IP) in a position of strength to negotiate a transaction with maximum regional impact. The collaboration with Triphase anchors R&D jobs, clinical trials and industrial development in Ontario, benefiting both the economy and patients.
Through financial support from Ontario's Ministry of Colleges and Universities, FACIT has a mandate to translate Ontario's most promising cancer innovations and maximize the value of the province's investment in research and healthcare. With a portfolio that has attracted over $850 million in investment to Ontario, FACIT is actively building companies with entrepreneurs to accelerate healthcare innovation and retain IP value, jobs and industrial development in Canada. Its success in locally commercializing medical technology, health IT, imaging, and therapeutics is a direct result of the integration of outstanding science, Ontario First seed capital, and industry experience into a novel commercialization venture model. Not only have FACIT-supported ventures attracted remarkable life science financings, but every dollar invested by FACIT has attracted $20 dollars of private equity to the province.
"We are proud of the team's work to help demonstrate the value of seed-stage investing in the commercialization of Propellon and Triphase, and we thank CVCA for this honour and recognition by our industry peers," said Dr. David O'Neill, President of FACIT. "The rapid growth of our portfolio demonstrates the power of biotechnology to capitalize on Ontario's world-class cancer science, compete in the innovation economy and make a difference in the fight against cancer."
"This is a great achievement and recognition that FACIT is successfully driving significant benefits to the Ontario innovation economy, building on the research strength of OICR," said Dr. Laszlo Radvanyi, President and Scientific Director of OICR.
"Congratulations to FACIT on receiving the CVCA award for their leadership in Ontario's commercialization sector," said the Honourable Ross Romano, Minister of Colleges and Universities. "FACIT has made smart and strategic investments in Ontario's rapidly developing biotech sector. The firm is an important partner in ensuring that the province's intellectual property is captured, both for the local economy and patients living with cancer."
About FACIT FACIT is a commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted over $850 million in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research (OICR), FACIT capitalizes on the province's investment in research and healthcare to the benefit of the local economy and patients worldwide. FACIT's commercialization portfolio includes Turnstone Biologics, Fusion Pharmaceuticals, Triphase Accelerator and other biotechnology organizations. Cancer Breakthroughs. Realized. facit.ca.
SOURCE FACIT Inc.
A CARDIAC SURGEON’S LIFE STORY SETS THE STAGE FORAN INSPIRATIONAL GUIDE TO UNLEASHING PEOPLE’S FULL POTENTIALIn HEART TO BEAT
, Dr. Brian Lima Challenges Readers To Strive For Greatness And Never Settle For Second Best College, medical school, and then ten years of grueling surgical training, that’s what it took for Brian Lima to become a leading heart transplant surgeon – literally able to breathe new life into critical ill patients. Not only has Lima never shied away from a challenge, he has spent his life actively seeking them in pursuit of seemingly near-impossible goals. In his insightful new book, HEART TO BEAT: A Cardiac Surgeon’s Inspiring Story of Success and Overcoming Adversity—The Heart Way (Clovercroft Publishing/February 18, 2020), Dr. Lima shares his story, giving everyone – not just aspiring physicians – the tools and encouragement needed to be their best selves.“We all have free will, and we all have a choice,” he writes. “You can choose to live aimlessly, halfheartedly going with the flow and suppressing that inner voice, the one beckoning you to unleash your full potential and to grab the world by storm. Or you can achieve success by committing to hard work and unceasing effort.”In HEART TO BEAT, Dr. Lima candidly shares, often with a wry sense of humor, how this approach enabled him to reach the pinnacle of success in all of his undertakings – whether it was building the strength and skill to become a varsity football player, becoming valedictorian of his high school class, earning a scholarship to Cornell University, or winning coveted residency opportunities as he trained to become a heart surgeon.“You don’t have to be the smartest or most talented person in the room to get ahead, just the one who wants it the most,” he writes. Indeed, Dr. Lima credits his own achievements purely to his intense effort. In his eminently readable, down-to-earth book, he breaks down the keys to advancing beyond your comfort zone and perceived limitations to unleash your full potential. Dr. Lima’s powerful lessons include:Heart Over Matter – “You, and you alone, are responsible for how much or how little you achieve in this life,” he writes. Only when you realize that you are master of your own destiny, and refuse to allow insecurities, past experiences, and fears to limit your potential, will you realize your dreams.Heart Of War – Complacency is your biggest adversary. You must never cease working and bettering yourself – if you do, you will surely slide off the top of your game. “The minute you rest on your laurels and kick your feet up, you’ve settled for defeat,” says Dr. Lima.Kickstart My Heart – Dr. Lima explains that the “propulsive power of ambition” has been one of the most impactful forces of his life. “Your eagerness to move ahead contributes more to your success than natural talent or being born with a silver spoon.” Ambition is what enables people to overcome the primary hurdle to success: self-doubt.Till Death With My Heart – If something is truly your calling – meaningful, bigger than you, and well-intended – it is likely not going to be easy to achieve, says Dr. Lima. For him, the rule must be “it’s all in or no win.” Being “well-rounded” is incompatible with true excellence, he contends.Not For the Faint of Heart – Fear of failure can disrupt the pursuit of any goal, and overcoming this fear is a monumental task that requires you to meet it head-on again and again, until you’re desensitized to its paralyzing influence. Dr. Lima urges readers to see every moment as just that – a moment – whether they’re going for a buzzer beater in basketball or performing heart surgery. This is what gives people the courage to take their shot at every opportunity.The Heart Sell on Entrepreneurship – “One way or another, you have to get the word out about how great your ‘brand’ is – in other words, how great you are,” says Dr. Lima, contending that the sales mantra “always be closing” is critical to success. He points to such key fundamentals as avoiding pigeonholes and being open to opportunities; never second-guessing yourself; continuing to invest in yourself; and using your time wisely.In addition to the author’s compelling personal story, HEART TO BEAT also includes a fascinating look at the current technologies and medical care available to treat heart disease, along with the basics about living a heart-healthy life – straight from the mouth of one of the country’s leading heart transplant surgeons.“There are those who choose to chase victory and to live life on their own terms, and there are those who don’t,” declares Dr. Lima. HEART TO BEAT will help you choose the path to victory, giving you the motivation you need to achieve your dreams, whatever they may be.# # #ABOUT THE AUTHORDr. Brian Lima is a cardiac surgeon, associate professor of surgery, and recognized authority in advanced heart failure. He has published nearly 80 articles in peer-reviewed medical journals and presented at numerous national and international medical conferences. As the surgical director of heart transplantation at North Shore University Hospital, Dr. Lima helped launch the first and only heart transplant program on Long Island. Dr. Lima completed his undergraduate studies at Cornell University and was awarded a Dean’s Full Tuition scholarship to attend Duke University School of Medicine. During medical school, Dr. Lima spent a year at Harvard Medical School’s Transplantation Biology Research Center as a Stanley Sarnoff cardiovascular research fellow. He then completed his general surgery residency training at Duke University Medical Center, and subsequent heart surgery training at The Cleveland Clinic, where he was awarded the prestigious Dr. Charles H. Bryan Annual Clinical Excellence Award in Cardiovascular Surgery
Both Feet on the Ground Shares Profoundly Therapeutic Benefits Of Immersion In The Natural World
Denver, CO, June 9, 2020 — You’re stressed out, tired of looking at the same four walls, drained by the negativity on social media, and exhausted from juggling work with homeschooling and entertaining your kids. No matter your age, location, or financial standing, there is a simple, effective therapy that is abundantly available, and it’s right outside your door.
“Get out and stay out—as often and for as long as you can,” champions Marshall Ulrich in his latest release, Both Feet on the Ground: Reflections from the Outside.
Ulrich, an ultrarunner who has also scaled the Seven Summits and competed in multi-day adventure races,shares stories of his expeditions in such far-flung places as Borneo, Tibet, and South Africa, as well as his lifelong commitment to farming his land in Colorado. Ulrich has climbed Mount Everest, run through the searing heat of the Gobi Desert, and ridden the huge waves off Morocco. But there’s no need to be an extreme athlete to reap the benefits of forming physical connections with the natural world.
Ulrich urges readers to simply unplug, plant their feet firmly in the earth, fill their lungs with clean air, and dream of bold and personally compelling outdoor adventures.
“Your adventures in natural places—even if, for now, it’s just sitting outside or walking around your neighborhood—can put you back in touch with who you are; how resilient, resourceful and hardy you can be,” Ulrich says.
Throughout Both Feet on the Ground, Ulrich shares valuable insights from his endeavors, along with useful findings and recommendations from other experts, all organized around themes of earth, air, fire and water. His hope is that you’ll be inspired to find new ways of engaging with these natural elements yourself to experience the healing powers of the outside world.
Author Marshall Ulrich is an extreme endurance athlete—ultrarunning icon, Seven Summits mountaineer, and adventure racer—who loves sharing his exploits to entertain and help motivate others to reach their goals. He’s raced, led expeditions, or climbed mountains in nearly 30 countries, and visited 30 more, so his stories are about more than just physical accomplishments. Cutting his teeth running across Death Valley, he’s also climbed Mount Everest, run in the jungles of Fiji, and completed a record-setting run across America. Dubbed the Endurance King, he defies the ideas of “too far,” “too old” and “not possible.” Revered among athletes, Marshall is also the author of Running on Empty. An acclaimed speaker, he’s lectured on various elite cruise lines, and given talks at businesses, schools, race expos, and professional conferences, including the Royal Geographic Society, Morgan Stanley, and Wilderness Medicine.
Working Toward a Race? How to Ease Into Starting a Running Schedule
Completing a running race, whether it is a 5k or a full marathon, is an accomplishment that should always be celebrated. Running is very rewarding, both physically and mentally. However, it also requires a great deal of patience and determination. If you have been injured and went to an ankle & foot clinic to get healed, or if you just have not regularly gone on runs in recent months, fear not. There is no rush in getting back into the groove of being in shape so that you can compete in a road race in the coming months.
Picking a Race and Date to Work Towards
The length of the race you want to run in is dependent on how long your training schedule should be. It is recommended that you start with a shorter race, such as a 5k or 10k, before jumping into anything longer. Once you have your date sought out, keep it marked, so that you can motivate yourself to work towards your goals each day as you approach race day.
Weekly Mileage and Pace
In terms of weekly mileage, start out small and progress as you increase your endurance each week. If you have not consistently run for the past few months, you should only strive for about 10-12 miles in three separate runs per week for the first couple weeks. Remember, your joints have not been used to running in a while, so it is important to ease into your return to prevent injury. Your pace can also go from conversational to slightly faster each week as your mileage slowly increases.
Impact of Cross-Training and Tracking Your Runs
Cross-training is also suggested to sustain an injury-free body and to build strength on the days in which you are not running. Keeping track of your distances and times for each run is also important and proves to be a motivating factor in improving your pace. Make it a habit that you run a few times each week, so that you can stick to your schedule and remain engaged in easing back into running as you set personal goals.
Run with a Smile
The most important factor to consider while you train and ease yourself into a running schedule to prepare for a race is maintaining a positive attitude. Running is frustrating, and it cannot be perfected overnight. Trust your process, and just know that each run you complete benefits you, no matter how long or how fast. Before you know it, you will have worked yourself into great shape in perfect time for race day.
Johnson & Johnson partnership to support frontline health workers in Sub Saharan Africa and the Middle East in fight against COVID-19
In response to COVID-19 pandemic Johnson & Johnson have formed a new partnership with The World Continuing Education Alliance, The Aga Khan University School of Nursing and Midwifery East Africa and the International Council of Nurses to support frontline health workers.
The result of this collaboration is the development of a focused training program that will be delivered via mobile app and aims to reach 600,000 nurses and midwives in Sub Saharan Africa and the Middle East.
The Aga Khan University (AKU) has established a certifiable COVID-19 Curriculum with 6 modules adapted from WHO training
The International Council of Nurses has supported through their collaboration with Nurses Associations, Nursing Councils and Ministries of Health
The World Continuing Education Alliance (WCEA) is bringing this knowledge to scale thanks to its virtual platform and mobile based training capacity.
Johnson and Johnson is funding the roll out across 10 priority countries in Sub-Saharan Africa namely: Kenya, Ethiopia, Uganda, Rwanda, Tanzania, Nigeria, South Africa, Ghana, Ivory Coast, Senegal. A roll out to Egypt, Jordan and other countries in the Middle East is yet to be confirmed
“One critical part of our response to COVID-19 is strengthening health systems by supporting and championing the people on the front lines who are at the heart of delivering care. Never has this ambition been more important than it is now as we face the biggest healthcare crisis in our lifetime” said Luis Diaz-Rubio, Managing Director, Janssen Emerging Markets, and a Board Member of the Johnson & Johnson Foundation (Scotland). ‘The partnership announced today will allow us to share more knowledge quickly and efficiently to many more frontline health workers which in turn will not only lead to better outcomes in the long run, but will help us beat this disease together’
The content developed for the app is open source and is currently available in English, Arabic and French. As well as enabling the program to reach a huge number of front-line workers the app will also encourage information sharing, creating effective and quick feedback channels which will in turn provide greater insight into the training needs and experience of those on the frontline in these countries.
“In response to COVID-19, with the aid of the Johnson & Johnson Foundation and our valuable training partners, The Aga Khan University School of Nursing and Midwifery East Africa, we are able to supply training resources to many more nurses, midwives and medical workers to assist in defeating the pandemic.” commented Craig Fitzpatrick, EMEA Director at the WCEA.
“Preparedness of nurses and midwives who are at the forefront in the fight against COVID-19 is critical to successfully dealing with the pandemic,” said Dr. Eunice Ndirangu, Dean of the School of Nursing and Midwifery (SONAM), Aga Khan University. Through the use of online and a mobile app, SONAM in partnership with Johnson and Johnson and WCEA is able to ensure access to nurses and midwives, even those in rural and hard to reach areas.”
“Ensuring nurses have the most up to date information, training and guidance on COVID-19 is a priority for ICN. We have a number of free resources, including the WCEA platform, available on our COVID-19 portal. This mobile app will be a helpful addition for nurses to ensure they are better prepared as the fight this pandemic.” Howard Catton, CEO, International Council of Nurses.
-------------ENDS-----------
About Johnson and Johnson: The Johnson & Johnson Center for Health Worker Innovation was founded to catalyze efforts to respond to the human resource crisis in global health and build a thriving health workforce. Leveraging a people-first model, the Center focuses on equipping nurses, midwives and community health workers across the globe with the skills, resources and support they need to improve quality of care and strengthen primary and community-based health systems.
About The World Continuing Education Alliance (WCEA): The WCEA works in partnership with the World Medical Association, the International Council of Nurses and other key collaboration partners focusing on supporting healthcare organizations to provide their frontline health workers access to education through online systems and mobile technology. In doing so, we work with respected educators to make their content available around the world.
About AKU: The Aga Khan University empowers the people of the developing world with the knowledge and skills to realize their highest goals. We provide a transformative education that prepares our graduates for local and global leadership. We generate solutions to problems that affect millions of people through pioneering research. We strive to achieve world-class excellence, inspiring individuals and institutions to meet the highest standards. Because everyone deserves the opportunity to fulfil their potential, we serve the disadvantaged and work where the need is greatest. Together with our partners, AKU builds bridges across borders and boundaries of all kinds, recognizing that humanity’s diversity is one of its greatest assets.
About the International Council of Nurses (ICN): The ICN is a federation of more than 130 national nurses’ associations representing the millions of nurses worldwide. Operated by nurses and leading nursing internationally, ICN works to ensure quality care for all and sound health policies globally.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!